MARLBOROUGH, Mass.,
April 4, 2018 /PRNewswire/
-- RXi Pharmaceuticals Corporation, a biotechnology company
developing immuno-oncology therapeutics based on its proprietary
self-delivering RNAi (sd-rxRNA®) therapeutic platform today
announced that it will present new data from the Company's
Dermatology Franchise at the International Investigative
Dermatology (IID) Conference. This conference unites three
leading dermatology societies, the European Society of
Dermatological Research (ESDR), the Journal of Investigative
Dermatology (JSID) and the Society of Investigational Dermatology
(SID), into one meeting that takes place every five years.
The 2018 IID will hold its seventh meeting this year, where
scientists and industry leaders gather from across the world to
exchange information and facilitate collaboration. This meeting is
being held May 16-19, 2018 at Rosen
Shingle Creek Resort in Orlando,
Florida.
- RXI-109 Treatment to Reduce the Formation of Hypertrophic
Dermal Scars
RXI-109: sd-rxRNA targeting
connective tissue growth factor (CTGF)
Date and Time: Thursday, May 17,
2018, 11:45 am – 1:45 p.m.
Session: Clinical Research, Pathophysiology and
Therapeutics
Poster #: 496, Gatlin Ballroom
- Samcyprone™ (diphenylcyclopropenone ointment) for the
Treatment of Common Warts
Samcyprone:
small molecule, proprietary topical formulation of
diphenylcyclopropenone (DPCP)
Date and Time: Friday, May 18,
2018, 12:00 pm – 2:00 p.m.
Session: Clinical Research, Pathophysiology and
Therapeutics
Poster #: 490, Gatlin Ballroom
- Topical Administration of self-delivering RNAi (sd-rxRNA)
Compounds for the Reduction of
Hyperpigmentation
RXI-231: sd-rxRNA
targeting tyrosinase (TYR)
Date and Time: Friday, May 18,
2018, 12:00 pm – 2:00 p.m.
Session: Pigmentation and Melanoma
Poster #: 1257, Gatlin Ballroom
Logo:
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
The posters will be available under the "Investors – Events
& Presentations" section of the Company's
website, www.rxipharma.com approximately 1 hour following
each presentation.
About RXi's Dermatology Franchise
RXi announced in January 2018 that
its would exclusively focus on developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
therapeutic platform. As such, it is actively seeking to
partner or out-license both its Dermatology and Ophthalmology
Franchises.
Each of these Franchises is comprised of a number of preclinical
and clinical-stage assets broadly covered by a robust intellectual
property estate. To obtain more information about these assets,
contact RXi's Director of Business Development, Dr. James Cardia at
jcardia@rxipharma.com
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing immuno-oncology therapeutics based
on its sd-rxRNA therapeutic platform. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including sd-rxRNA compounds, that has
the potential to highly selectively block the expression of any
target in the genome, thus providing applicability to many
therapeutic areas. RXi's extensive patent portfolio provides
for multiple product and business development opportunities across
a broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™,
RXI-762, RXI-804 and our other product candidates (collectively
"our product candidates"); the future success of our clinical
trials with our product candidates; the timing for the commencement
and completion of clinical trials; our ability to enter into
strategic partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-an-update-on-its-clinical-and-cosmetic-dermatology-programs-at-the-international-investigative-dermatology-conference-300623969.html
SOURCE RXi Pharmaceuticals Corporation